Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Symphogen

Status and phase: Withdrawn; Phase 2

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Sym004

Study type: Interventional

Funder types: Industry

Identifiers

NCT02965417

2016-000621-39 (EudraCT Number)

Sym004-11

Details and patient eligibility

About

This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion and Exclusion criteria have been removed due to Symphogen's business decision to no longer perform the clinical study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Sym004

Experimental group

Description:

All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions

Treatment:

Drug: Sym004